Spring Bank Pharmaceuticals announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate Spring Bank's hepatitis B virus antisense
oligonucleotide compounds.Spring Bank has entered into a non-clinical evaluation agreement to access NIAID's preclinical services program to further evaluate Spring Bank's HBV antisense
Brett is a founding member of Ionis, an outstanding scientist and a well-recognized expert in antisense
The contract has been signed for NEXAGON, a 30-base antisense
oligomer being developed for the orphan indication of persistent corneal epithelial defect nonresponsive to standard of care.
Biogen and Ionis Pharmaceuticals have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense
drug candidates for a broad range of neurological diseases.
Ionis granted Ribo a license to commercialize two Ionis Generation 2+ antisense
drugs in metabolic disease and cancer and an option to license a third Generation 2+ antisense
Kevin Morris will present evidence here suggesting that long non-coding RNAs (lncRNAs), which are antisense
to particular protein-coding genes, function in human cells as effector molecules driving endogenous TGS.
The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense
compound in treating Alzheimer's disease in humans.
We further focused on Sl-ERF.B.3 role in vegetative growth regulation against salt stress by characterizing two Sl-ERF.B.3 antisense
transgenic tomato lines compared to wild type, and we discussed the Sl-ERF.B.3 role in the layout of shoot and root growth changes related to adaptive responses to salinity.
have established an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense
oligonucleotide (ASO) technology.
To combat the toxic messenger RNA, the researchers used a class of drugs called "antisense
compounds." These compounds bind to abnormal RNA and wave down RNase H, an enzyme that chops up RNA.
This process involves replacement of the natural antisense
sequence with that tackles to the desired RNA  and becomes a new modality in advanced gene therapy for hemoglobinopathies.
To this end, the invention provides modified antisense
and sense RNA molecules, chimeric genes encoding such modified antisense
or sense RNA molecules and eukaryotic organisms such as plants, animals or fungi, yeast or molds, comprising the modified antisense
and/or sense RNA molecules or the encoding chimeric genes.